Skip to Main Content

Questions

Which of the following is not a risk factor for the development of breast cancer in women?

A. Early menarche

B. Increased age

C. Late menopause

D. All are risk factors for the development of breast cancer

D. All are risk factors for the development of breast cancer. Breast cancer is most often an estrogen mediated cancer so factors that would increase exposure to estrogen would be associated with an increases the risk of development of breast cancer including:

A. Early menarche and C. Late Menopause and risk increase over lifetime so B. Increased age is also a risk factor

Which of the following is (are) true regarding mutations to the BRCA genes:

A. Mutations result in a 10% increase in absolute risk of breast cancer

B. These mutations are the only genetic factors which influence breast cancer susceptibility

C. Mutations cause increase risk of other cancers including gynecologic cancers

D. A and C

C. Mutations cause increase risk of other cancers including gynecologic cancers – BRCA 1 and BRCA 2 are also associated with development of epithelial ovarian cancer – often called "Hereditary Breast Ovarian Family Syndrome".

A. is incorrect because while the rate of BRCA mutations does increase absolute risk of breast cancer but at a greater rate and B. is incorrect because as mentioned, is not only associated with development of breast cancer.

Both tamoxifen and raloxifene are methods which can be effective in reducing the risk of breast cancer in high risk women, which statement is true comparing tamoxifen and raloxifene:

A. Tamoxifen use resulted in less in situ tumor formation compared to raloxifene

B. The raloxifene group suffered more DVT than tamoxifen

C. Treatment with raloxifene increased the incidence of uterine hyperplasia to a greater degree than tamoxifen

D. Raloxifene was superior in preventing breast cancer when compared to tamoxifen

A. Tamoxifen use resulted in less in situ tumor formation compared to raloxifene is correct answer however the two have been deemed equally effective in randomized, controlled phase III studies, tamoxifen does tend to be preferred agent in clinical practice.

B. Is incorrect because incidence of DVT is actually more common with tamoxifen due to its ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.